Literature DB >> 9613560

Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson's disease with autonomic failure.

S Braune1, M Reinhardt, J Bathmann, T Krause, M Lehmann, C H Lücking.   

Abstract

OBJECTIVE: To selectively investigate postganglionic sympathetic cardiac neurons in patients with Parkinson's disease and autonomic failure.
MATERIAL AND METHODS: Metaiodobenzylguanidine (MIBG) is a pharmacologically inactive analogue of noradrenaline, which is similarly metabolized in noradrenergic neurons. Therefore the uptake of radiolabelled MIBG represents not only the localization of postganglionic sympathetic neurons but also their functional integrity. Ten patients with Parkinson's disease and autonomic failure underwent standardized autonomic testing, assessment of catecholamine plasma levels and scintigraphy with [123I]MIBG.
RESULTS: The cardiac uptake of MIBG, as demonstrated by the heart/mediastinum ratio, was significantly lower in patients in comparison with controls. Scintigraphy with MIBG allowed the selective in-vivo investigation of postganglionic sympathetic cardiac efferents in patients with autonomic failure, a procedure which was previously confined to post-mortem examination.
CONCLUSION: These findings point to a relevant postganglionic pattern of involvement of the autonomic nervous system (ANS) in Parkinson's disease and autonomic failure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613560     DOI: 10.1111/j.1600-0404.1998.tb05958.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  24 in total

Review 1.  Cardiac sympathetic neuroimaging to distinguish multiple system atrophy from Parkinson disease.

Authors:  D S Goldstein
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

Review 2.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

3.  Premotor Parkinson's disease: concepts and definitions.

Authors:  Andrew Siderowf; Anthony E Lang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

Review 4.  Early diagnosis of Parkinson's disease.

Authors:  Jörg Spiegel; Alexander Storch; Wolfgang H Jost
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

Review 5.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

Review 6.  Preclinical diagnosis of Parkinson's disease: are we there yet?

Authors:  Andrew Siderowf; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

Review 7.  The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes.

Authors:  S Braune
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

Review 8.  Dysautonomia in Parkinson disease.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

9.  Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease.

Authors:  K Hamada; M Hirayama; H Watanabe; R Kobayashi; H Ito; T Ieda; Y Koike; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

10.  I-123 MIBG cardiac scintigraphy and autonomic test evaluation in multiple sclerosis patients.

Authors:  Mordechai Lorberboym; Yair Lampl; Galina Nikolov; Menachem Sadeh; Ronit Gilad
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.